Search research articles
Contact Us
Filters
Showing results (1021-1030 of 1,111) with videos related to
Page
of 112
Sort By:
Nature
|
June 30, 2016
Vaccine protection against Zika virus from Brazil
Rafael A Larocca, Peter Abbink, Jean Pierre S Peron, et al.
Plos Pathogens
|
May 31, 2023
Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response
LaTonya D Williams, Xiaoying Shen, Sheetal S Sawant, et al.
Plos One
|
February 8, 2014
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection
Susan Zolla-Pazner, Allan deCamp, Peter B Gilbert, et al.
Journal of Virology
|
August 17, 2012
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family
Mattia Bonsignori, Justin Pollara, M Anthony Moody, et al.
NPJ Vaccines
|
May 23, 2024
Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy
Boris Julg, Kathryn E Stephenson, Frank Tomaka, et al.
The Journal of Infectious Diseases
|
March 23, 2017
Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial
Supachai Rerks-Ngarm, Punnee Pitisuttithum, Jean-Louis Excler, et al.
Ebiomedicine
|
September 11, 2022
Long-term antiretroviral therapy initiated in acute HIV infection prevents residual dysfunction of HIV-specific CD8<sup>+</sup> T cells
Hiroshi Takata, Juyeon C Kakazu, Julie L Mitchell, et al.
The Journal of Infectious Diseases
|
August 30, 2014
Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses
Genevieve G Fouda, Coleen K Cunningham, Elizabeth J McFarland, et al.
The Journal of Infectious Diseases
|
October 3, 2017
Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost
Julie A Ake, Alexandra Schuetz, Poonam Pegu, et al.
Journal of Virology
|
November 29, 2019
Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency
David Easterhoff, Justin Pollara, Kan Luo, et al.
Page
of 112
Search research articles
Search
Showing results (1021-1030 of 1,111) with videos related to
Sort By:
Page
of 112
Nature
|
June 30, 2016
Vaccine protection against Zika virus from Brazil
Rafael A Larocca, Peter Abbink, Jean Pierre S Peron, et al.
Plos Pathogens
|
May 31, 2023
Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response
LaTonya D Williams, Xiaoying Shen, Sheetal S Sawant, et al.
Plos One
|
February 8, 2014
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection
Susan Zolla-Pazner, Allan deCamp, Peter B Gilbert, et al.
Journal of Virology
|
August 17, 2012
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family
Mattia Bonsignori, Justin Pollara, M Anthony Moody, et al.
NPJ Vaccines
|
May 23, 2024
Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy
Boris Julg, Kathryn E Stephenson, Frank Tomaka, et al.
The Journal of Infectious Diseases
|
March 23, 2017
Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial
Supachai Rerks-Ngarm, Punnee Pitisuttithum, Jean-Louis Excler, et al.
Ebiomedicine
|
September 11, 2022
Long-term antiretroviral therapy initiated in acute HIV infection prevents residual dysfunction of HIV-specific CD8<sup>+</sup> T cells
Hiroshi Takata, Juyeon C Kakazu, Julie L Mitchell, et al.
The Journal of Infectious Diseases
|
August 30, 2014
Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses
Genevieve G Fouda, Coleen K Cunningham, Elizabeth J McFarland, et al.
The Journal of Infectious Diseases
|
October 3, 2017
Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost
Julie A Ake, Alexandra Schuetz, Poonam Pegu, et al.
Journal of Virology
|
November 29, 2019
Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency
David Easterhoff, Justin Pollara, Kan Luo, et al.
Page
of 112